Group 1 - The company is currently constructing a 7,000-ton VC additive project, expected to be operational by Q4 2026, with no plans for LIFSI or other additives at this time [2] - The company has established a comprehensive pharmaceutical industry chain, with products sold to dozens of countries and regions globally, and has formed good partnerships with well-known pharmaceutical companies [2] - The company aims to continue the integrated development of high-end active pharmaceutical ingredients, specialty pharmaceutical intermediates, and pharmaceutical formulations, while expanding its international market presence and actively promoting the approval of generic drugs in the domestic market [2]